According to the Zhitong Finance App, Jingfeng Medical-B (02675) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 319 million (same unit), an increase of 113.8% over the previous year; the loss attributable to the equity shareholders of the Company was 19.254 million yuan, a decrease of 78.4% year on year; loss per share was 0.05 yuan.

According to the announcement, the increase in revenue was mainly due to a sharp increase in overseas sales of Jingfeng® porous endoscopic surgical robots. The main reason for the sharp increase in foreign sales is that the Group has established overseas sales teams and distributor agreements. Based on the performance, clinical stability and marketing initiatives of the Group's surgical robots, the commercialization of Jingfeng® porous endoscopic surgical robots in overseas markets has contributed to a significant increase in revenue.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.